ReviewClinical reviews in allergy & immunology2021
Inflammasomes and Childhood Autoimmune Diseases: A Review of Current Knowledge.
Review in Clinical reviews in allergy & immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Preliminary IL-1 Family Cytokine Signature for Crohn's Disease Onset in Pediatric Juvenile Idiopathic Arthritis.International journal of molecular sciences · 2026Article
- Case Report: Safety and efficacy of combination therapy with adalimumab and anakinra in two patients with severe inflammatory diseases.Frontiers in pediatrics · 2026Article
- Ocimene mitigates pyroptosis through TLR4/NLRP3-mediated mechanisms in CFA-induced inflammation.Inflammopharmacology · 2025Article
- Cardio-Rheumatic Diseases: Inflammasomes Behaving Badly.International journal of molecular sciences · 2025Review
- NLRP3 overexpression exacerbated synovium tissue degeneration in juvenile collagen-induced arthritis.Scientific reports · 2025Article
- The Role of Pyroptosis-Related Gene Signature and Immune Infiltration in Juvenile Dermatomyositis.Clinical, cosmetic and investigational dermatology · 2025Article
- Association of Long Noncoding RNA Expression Signatures with Stress-Induced Myocardial Perfusion Defects.Biomolecules · 2023Article
- Inflammasome activation and formation of ASC specks in patients with juvenile idiopathic arthritis.Frontiers in medicine · 2023Article
- Innate immune response analysis in COVID-19 and kawasaki disease reveals MIS-C predictors.Journal of the Formosan Medical Association = Taiwan yi zhi · 2022Article
- Expression of Autoimmunity-Related Genes in Melanoma.Cancers · 2022Article
- Nod-like Receptors: Critical Intracellular Sensors for Host Protection and Cell Death in Microbial and Parasitic Infections.International journal of molecular sciences · 2021Review
- Monogenic Autoinflammatory Diseases: State of the Art and Future Perspectives.International journal of molecular sciences · 2021Review
- Socioeconomic and Racial and/or Ethnic Disparities in Multisystem Inflammatory Syndrome.Pediatrics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammasomes are multiprotein complexes capable of sensing pathogen-associated molecular patterns (PAMPs), danger-associated molecular patterns (DAMPs), and cellular perturbations. Upon stimulation, the inflammasomes activate the production of the pro-inflammatory cytokines IL-1β and IL-18 and induce gasdermin D-mediated pyroptosis. Dysregulated inflammasome signaling could lead to hyperinflammation in response to environmental triggers, thus contributing to the pathogenesis of childhood autoimmune/autoinflammatory diseases. In this review, we group childhood rheumatic diseases into the autoinflammation to autoimmunity spectrum and discuss about the involvement of inflammasomes in disease mechanisms. Genetic mutations in inflammasome components cause monogenic autoinflammatory diseases, while inflammasome-related genetic variants have been implicated in polygenic childhood rheumatic diseases. We highlight the reported associations of inflammasome signaling-related genetic polymorphisms/protein levels with pediatric autoimmune disease susceptibility and disease course. Furthermore, we discuss about the use of IL-1 receptor antagonist as an adjunctive therapy in several childhood autoimmune diseases, including macrophage activation syndrome (MAS) and multisystem inflammatory syndrome in children (MIS-C) related to COVID-19. A comprehensive multi-cohort comparison on inflammasome gene expression profile in different pediatric rheumatic diseases is needed to identify patient subsets that might benefit from the adjunctive therapy of IL-1β inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.